Last reviewed · How we verify

LY2963016

Eli Lilly and Company · Phase 3 active Small molecule

LY2963016 is a long-acting basal insulin analog that binds to the insulin receptor to regulate blood glucose by promoting glucose uptake and storage.

LY2963016 is a long-acting basal insulin analog that binds to the insulin receptor to regulate blood glucose by promoting glucose uptake and storage. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

At a glance

Generic nameLY2963016
SponsorEli Lilly and Company
Drug classBasal insulin analog
TargetInsulin receptor
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 3

Mechanism of action

LY2963016 is a biosynthetic insulin glargine designed to provide steady, long-acting glycemic control in diabetes patients. It mimics endogenous insulin by activating insulin receptors on muscle and adipose tissue, facilitating glucose uptake and suppressing hepatic glucose production. The formulation is engineered for extended duration of action to reduce dosing frequency.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: